VIA EDGAR
Division of Corporation Finance
U.S. Securities and Exchange Commission
100 F Street,
NE Washington, D.C. 20549
August 16, 2022
Re:Facible BioDiagnostics, Inc.
Post Qualification Amendment No. 1 to Offering Statement on Form 1-A
File No. 024-11878
To Whom It May Concern:
On behalf of Facible BioDiagnostics, Inc. (the “Company”), I hereby request qualification of the above-referenced amended offering statement at 2:00PM, Eastern Time, on Friday, August 19, 2022, or as soon thereafter as is practicable.
Sincerely,
/s/ Dr. Steven Burden, Ph.D.
Dr. Steven Burden, Ph.D.
Director, Chief Executive Officer, President
Facible BioDiagnostics, Inc.